Eli Lilly's stock is predicted to rise nearly 19% over the next year, driven by rapid growth in its oncology, immunology, and neuroscience drug portfolios, which grew 121% year-over-year last quarter. While known for weight loss drugs like Mounjaro and Zepbound, the company is expanding with new products such as the oral GLP-1 Foundayo and Retatrutide, targeting diabetes and obesity-related conditions. Despite pricing pressures and competition, strong revenue and earnings beats have led to raised full-year guidance, supporting a bullish outlook with a price target of $1,359.12. Investors should watch regulatory approvals and pricing trends as key factors for future performance.
Eli Lilly's stock trades at USD 1,161.66 on Pluang as of Oct 07, 2026 00:11 WIB, which is below its 52-week high of $1.28K but well above its 52-week low of $799.57. The stock has gained 1.62% in the last day and shows a strong market cap of $1.02 trillion. Despite some pricing pressures noted in the news, the Pluang order activity leans bullish with 65% of investors buying versus 35% selling, reflecting continued investor interest.
Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. ...
The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is ...
Eli Lilly reported a 47.7% revenue increase to $22.97 billion in Q2 2026, surpassing expectations and raising its full-year revenue guidance to $85-$87 billion. The company’s stock trades near $1,185 with a 24/7 Wall St. price target of $1,401, sugge...
Eli Lilly announced promising mid-stage trial results for EloraTZP, a new obesity drug that led to up to 23.3% weight loss in overweight or obese type 2 diabetes patients after 48 weeks, outperforming Novo Nordisk's tirzepatide alone. The drug also s...
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
